Literature DB >> 24649341

Clinical characteristics and prognostic analysis of triple-negative breast cancer patients.

Na Yuan1, Min Meng1, Caigang Liu2, Lu Feng1, Lei Hou1, Qian Ning1, Guohong Xin1, Li Pei1, Shanzhi Gu3, Xiao Li4, Xinhan Zhao1.   

Abstract

It is well-established that triple-negative breast cancer (TNBC) is a subtype of breast cancer, characterized by a poor prognosis and aggressive biological behavior. However, the available relevant data on TNBC in non-Western populations are limited. In order to analyze the clinicopathological and molecular biological characteristics and observe survival and prognostic factors, 972 breast cancer patients (156 of whom had TNBC) who received treatment at the First Affiliated Hospital of Medical School of Xi'an Jiaotong University and the First Hospital of China Medical University, between January, 2004 and January, 2007 were retrospectively evaluated. In the univariate analysis, tumor size, TNM stage, axillary lymph node status and recurrence or metastasis were identified as prognostic factors for 7-year disease-free survival (DFS) and overall survival (OS). Our multivariate Cox's regression analysis demonstrated that tumor size and axillary lymph node status were significant prognostic factors for 7-year DFS and OS. Notably, tumor subgroup (TNBC vs. non-TNBC) was a significant prognostic factor associated with 7-year DFS and OS in breast cancer. It was suggested that TNBC exhibited a worse 7-year survival compared with that in non-TNBC patients, most likely due to its more aggressive behavior and insensitivity to specific therapy.

Entities:  

Keywords:  clinicopathological characteristics; prognostic analysis; survival analysis; triple-negative breast cancer

Year:  2013        PMID: 24649341      PMCID: PMC3917786          DOI: 10.3892/mco.2013.230

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  29 in total

1.  A 10-year follow-up of triple-negative breast cancer patients in Taiwan.

Authors:  Che Lin; Su-Yu Chien; Shou-Jen Kuo; Li-Sheng Chen; Shou-Tung Chen; Hung-Wen Lai; Tsai-Wang Chang; Dar-Ren Chen
Journal:  Jpn J Clin Oncol       Date:  2012-01-27       Impact factor: 3.019

2.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  Makiko Ono; Hitoshi Tsuda; Chikako Shimizu; Sohei Yamamoto; Tatsuhiro Shibata; Harukaze Yamamoto; Taizo Hirata; Kan Yonemori; Masashi Ando; Kenji Tamura; Noriyuki Katsumata; Takayuki Kinoshita; Yuichi Takiguchi; Hideki Tanzawa; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2011-05-12       Impact factor: 4.872

3.  Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

Authors:  David G Hicks; Sarah M Short; Nichole L Prescott; Shannon M Tarr; Kara A Coleman; Brian J Yoder; Joseph P Crowe; Toni K Choueiri; Andrea E Dawson; G Thomas Budd; Raymond R Tubbs; Graham Casey; Robert J Weil
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

4.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

5.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

8.  Is triple negative a prognostic factor in breast cancer?

Authors:  Reiki Nishimura; Nobuyuki Arima
Journal:  Breast Cancer       Date:  2008-03-29       Impact factor: 4.239

9.  HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells.

Authors:  Sandeep N Shah; Leslie Cope; Weijie Poh; Amy Belton; Sujayita Roy; C Conover Talbot; Saraswati Sukumar; David L Huso; Linda M S Resar
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

10.  TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Authors:  Virginie Maire; Céline Baldeyron; Marion Richardson; Bruno Tesson; Anne Vincent-Salomon; Eléonore Gravier; Bérengère Marty-Prouvost; Leanne De Koning; Guillem Rigaill; Aurélie Dumont; David Gentien; Emmanuel Barillot; Sergio Roman-Roman; Stéphane Depil; Francisco Cruzalegui; Alain Pierré; Gordon C Tucker; Thierry Dubois
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more
  17 in total

1.  A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.

Authors:  Anja Bastian; Jessica E Thorpe; Bryan C Disch; Lora C Bailey-Downs; Aleem Gangjee; Ravi K V Devambatla; Jim Henthorn; Kenneth M Humphries; Shraddha S Vadvalkar; Michael A Ihnat
Journal:  J Pharmacol Exp Ther       Date:  2015-02-26       Impact factor: 4.030

Review 2.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

3.  The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.

Authors:  Yeşim Eralp; Leyla Kılıç; Gül Alço; Gül Başaran; Mutlu Doğan; Dilek Dinçol; Senem Demirci; Fikri İçli; Handan Onur; Pınar Saip; Ayfer Haydaroğlu
Journal:  J Breast Health       Date:  2014-10-01

4.  Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro.

Authors:  Lin-Lin Yin; Xin-Mian Wen; Qing-Hua Lai; Jing Li; Xiu-Wen Wang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

5.  Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer.

Authors:  Guang-Xu Liu; Yun-Cui Yu; Xiang-Ping He; Sheng-Nan Ren; Xue-Dong Fang; Fen Liu; Yan He
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis.

Authors:  Jiang-Bo Liu; Chen-Yi Feng; Miao Deng; Dong-Feng Ge; De-Chun Liu; Jian-Qiang Mi; Xiao-Shan Feng
Journal:  World J Surg Oncol       Date:  2017-08-01       Impact factor: 2.754

7.  Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.

Authors:  Ana Cláudia de Macêdo Andrade; Carlos Alberis Ferreira Júnior; Beatriz Dantas Guimarães; Ana Waleska Pessoa Barros; Gibran Sarmento de Almeida; Mathias Weller
Journal:  BMC Womens Health       Date:  2014-09-12       Impact factor: 2.809

8.  Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.

Authors:  Michael R Clemens; Oleg A Gladkov; Elaina Gartner; Vladimir Vladimirov; John Crown; Joyce Steinberg; Fei Jie; Anne Keating
Journal:  Breast Cancer Res Treat       Date:  2014-12-30       Impact factor: 4.624

9.  Harmonic Scalpel versus Electrocautery Dissection in Modified Radical Mastectomy for Breast Cancer: A Meta-Analysis.

Authors:  Jinbo Huang; Yinghua Yu; Changyuan Wei; Qinghong Qin; Qinguo Mo; Weiping Yang
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Inflammatory cytokine IL-8/CXCL8 promotes tumour escape from hepatocyte-induced dormancy.

Authors:  Ahmad S Khazali; Amanda M Clark; Alan Wells
Journal:  Br J Cancer       Date:  2017-11-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.